Sign In
Buy IUGNF
$0.0750
+0 (+0%)
At Close: Jul 13, 2026
Imugene and Eureka Therapeutics collaborate to accelerate advancement of oncolytic virus and T-cell therapy in solid tumours
06:12pm, Sunday, 31'st Oct 2021
Imugene Ltd and Eureka Therapeutics, Inc have entered into a strategic collaboration to evaluate Imugene's CD19 oncolytic virus onCARlytics technology in combination with Eureka's anti-CD19 ARTEMIS®
Imugene and City of Hope® dose first patient in Phase I clinical trial
12:51am, Wednesday, 20'th Oct 2021
Imugene Limited collaborator City of Hope® has dosed its first patient in its Phase I clinical trial of oncolytic virotherapy candidate, CHECKvacc. Along with City of Hope, a world-renowned independe
Imugene granted HER-Vaxx immunotherapy patent in Japan
01:11am, Wednesday, 22'nd Sep 2021
Imugene Limited, a clinical-stage immuno-oncology company, has received a notice of grant from the Japanese Patent Office for patent application number 2018-505505 which protects its HER-Vaxx immunoth
Imugene upgraded to Buy and target price boosted to 52 cents by Bell Porter on back of capital raise and new HER vaxx trials
03:01am, Friday, 03'rd Sep 2021
Imugene Limited (ASX:IMU, OTC:IUGNF) has received another boost with news that broker Bell Porter has upgraded the company's shares to a Buy (Speculative) from a Hold and more than doubling its target
Imugene reveals encouraging HER-Vaxx gastric cancer data, plans three new trials
10:52pm, Tuesday, 31'st Aug 2021
Imugene Limited, a clinical-stage immune-oncology company, has revealed secondary efficacy endpoint progression-free survival (PFS) data for its HER-Vaxx immunotherapy in HER-2 positive gastric cancer
Imugene welcomes phase-1 trial dosing schedule for third monotherapy cohort of immunotherapy PD1-Vaxx
08:02pm, Thursday, 26'th Aug 2021
Imugene Limited has welcomed the dosing schedule for the third monotherapy cohort of its phase-1 trial of the immunotherapy PD1-Vaxx on three patients. Barring any unforeseen clinical observations, th
Imugene concludes A$95 million raise with heavily oversubscribed share purchase plan
07:17pm, Thursday, 19'th Aug 2021
Imugene Limited has raised A$5 million in a heavily oversubscribed share purchase plan (SPP), capping off a A$95 million capital raise to fund its clinical pipeline into 2025. The clinical-stage immun
Imugene details the fine print on Celularity partnership
01:59am, Tuesday, 10'th Aug 2021
Imugene Limited has provided additional information on a recent partnership with NASDAQ-listed biotech Celurlarity Inc. The clinical-stage immune-oncology company told the local share market it had pa
Imugene ends June 2021 quarter with $29.5m cash balance and strong focus on research and development
01:28am, Monday, 09'th Aug 2021
Imugene Limited (ASX:IMU) (OTCMKTS:IUGNF) is well-funded and ready to progress to human studies for its CF33 and PD1-Vaxx treatments in the near-term as well as continuing enrolment into the HER-Vaxx
Imugene enters into strategic partnership with Celularity to develop immunotherapy for solid tumors
10:21pm, Wednesday, 04'th Aug 2021
Imugene Ltd has entered into a research collaboration with Celurlarity Inc to develop a novel oncolytic virus allogeneic CAR T-Cell immunotherapy combination for the treatment of solid tumors. As part
